Indivior PLC (INDV) Stock Forecast & Price Target

Indivior PLC has demonstrated strong growth potential, highlighted by a significant 8% increase in the number of patients receiving Sublocade treatment, reaching approximately 171,500 in the third quarter of 2025. Additionally, the company reported an 11% rise in the number of prescribers for Sublocade, totaling around 8,568, which underscores its expanding market presence. Furthermore, management's upward revision of worldwide sales guidance for Sublocade to a range of $825 million to $845 million indicates confidence in a continued trajectory of annual growth of approximately 10%, driven by increasing adoption of Medication-Assisted Treatments (MATs).

Indivior PLC faces a negative outlook primarily due to the anticipated decline in Suboxone revenue resulting from increasing generic competition, which raises concerns about overall revenue stability. Although Sublocade is projected to generate growth, its current position in the early stages of its commercial lifecycle suggests that it may not sufficiently offset the revenue losses from Suboxone in the near term. Additionally, the company's elevated selling, general, and administrative (SG&A) expenses, estimated at approximately 45% of revenue in 2026, may further strain profitability amidst these revenue challenges.